Letter by Hsieh and Lin Regarding Article, “Acute Reperfusion Therapy and Stroke Care in Asia After Successful Endovascular Trials”
To the Editor:
We agree with Toyoda et al1 to reconsider the different responses of Asian patients with stroke to reperfusion and other acute treatments in the era after successful endovascular trials. With the improvement of infrastructure, Asian strokologists nowadays are more capable of conducting international randomized, double-blinded, placebo-controlled trials to develop new regimens. For example, the Chinese Medicine NeuroAiD Efficacy on Stroke Recovery-Extension Study (CHIMES-E), which examined the effects of the initial 3-month treatment with MLC601 (NeuroAid, a Chinese herbal product) on long-term outcome for ≤2 years, shows positive results, although the primary efficacy end point is not reached statistically.2 An ongoing phase III stroke trial conducted in Taiwan is to test the neuroprotective efficacy of BNG-1,3 another Chinese herbal product.4 Concerning the unique features of Asian patients with stroke, strokologists in Asia are endeavoring to apply the scientific methods of Western medicine to explore solutions more suitable for their patients from the ancient local wisdom.
Cheng-Yang Hsieh, MD, PhD
Department of Neurology, Tainan Sin Lau Hospital, Tainan, Taiwan
Huey-Juan Lin, MD, MPH
Department of Neurology, Chi Mei Medical Center, Tainan, Taiwan
Stroke welcomes Letters to the Editor and will publish them, if suitable, as space permits. Letters must reference a Stroke published-ahead-of-print article or an article printed within the past 3 weeks. The maximum length is 750 words including no more than 5 references and 3 authors. Please submit letters typed double-spaced. Letters may be shortened or edited.
- © 2015 American Heart Association, Inc.
- Toyoda K,
- Koga M,
- Hayakawa M,
- Yamagami H.
- 3.↵Efficacy of BNG-1 to Treat Acute Ischemic Stroke. ClinicalTrials.gov Web site. https://clinicaltrials.gov/ct2/show/NCT01675115?term=bng-1&rank=1. Accessed May 31, 2015.